CHOSA Oncology expanded its DRP® platform to predict responses to both cisplatin and carboplatin, advancing studies in lung and breast cancer. Q1 2025 saw a net loss of -1,807 TSEK and strong equity ratio, with key clinical milestones expected in Q2.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.